Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904617 | 1.00 | BDKRB1 (0.50) | BDKRB1ALDH1A1TSHRHTTNPSR1 | |
| SCHEMBL21179112 | 0.94 | TSHR (0.49) | BDKRB1ALDH1A1TSHRHTTNPSR1 | |
| SCHEMBL21284635 | 0.90 | ALDH1A1 (0.45) | BDKRB1ALDH1A1TSHRHTTNPSR1 | |
| SCHEMBL21178816 | 0.87 | BDKRB1 (0.62) | BDKRB1HDAC4HDAC6GPR119 | |
| SCHEMBL21178414 | 0.87 | BDKRB1 (0.51) | BDKRB1HDAC4HDAC6 | |
| SCHEMBL21178498 | 0.86 | ALDH1A1 (0.48) | BDKRB1ALDH1A1TSHRHTTNPSR1 | |
| SCHEMBL21270942 | 0.86 | CA12 (0.47) | BDKRB1ALDH1A1TSHRHTTNPSR1 | |
| SCHEMBL21178499 | 0.86 | ALDH1A1 (0.48) | BDKRB1ALDH1A1TSHRHTTNPSR1 | |
| SCHEMBL21270944 | 0.86 | CA12 (0.47) | BDKRB1ALDH1A1TSHRHTTNPSR1 | |
| SCHEMBL21284640 | 0.86 | ALDH1A1 (0.42) | BDKRB1ALDH1A1TSHRHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4491622-A2 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-3740481-B9 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12065436-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-3740481-B1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3999180-B1 | POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | CYTOKINETICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117964573-A | Dihydrobenzofuran and indene analogs as myocardial segment inhibitors | 赛特凯恩蒂克公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117924208-A | Dihydrobenzofuran and indene analogs as myocardial segment inhibitors | 赛特凯恩蒂克公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3999038-B1 | CARDIAC SARCOMERE INHIBITOR ORAL FORMULATIONS | CYTOKINETICS INC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-111757875-B | Dihydrobenzofuran and indene analogs as myocardial segment inhibitors | 赛特凯恩蒂克公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2021011807-A1 | POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | CYTOKINETICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011808-A1 | CARDIAC SARCOMERE INHIBITOR ORAL FORMULATIONS | CYTOKINETICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-3740481-A1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-111757875-A | Dihydrobenzofuran and indene analogs as inotropic agents | 赛特凯恩蒂克公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
| WO-2019144041-A1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836755-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885ALDH1A1 3390/4885TSHR 2655/4885 |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885ALDH1A1 3390/4885TSHR 2655/4885 |
| US-12065436-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885ALDH1A1 3390/4885TSHR 2655/4885 |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885ALDH1A1 3390/4885TSHR 2655/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885ALDH1A1 3390/4885TSHR 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.